Identification of prognostic DNA methylation biomarkers in patients with gastrointestinal adenocarcinomas: A systematic review of epigenome-wide studies.
Biomarker
DNA methylation
Epigenetics
GI adenocarcinoma
Methylation array
Journal
Cancer treatment reviews
ISSN: 1532-1967
Titre abrégé: Cancer Treat Rev
Pays: Netherlands
ID NLM: 7502030
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
20
07
2019
revised:
14
11
2019
accepted:
15
11
2019
pubmed:
1
12
2019
medline:
10
1
2020
entrez:
1
12
2019
Statut:
ppublish
Résumé
This systematic review aims to summarize epigenome-wide studies on aberrant DNA methylation and its association with survival in patients with gastrointestinal adenocarcinoma. The 15 studies identified showed a large variety of methodological approaches for the identification of prognostic epigenetic markers from genome-wide methylation analyses. None of the findings were reported by more than one study in this systematic review. Further validation studies, a better reporting of methods and results are needed, as well as a clearer definition of investigated outcomes. At present, no conclusions can be drawn on the clinical relevance of the reported epigenetic markers.
Identifiants
pubmed: 31785412
pii: S0305-7372(19)30154-9
doi: 10.1016/j.ctrv.2019.101933
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101933Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.